pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Weekly maintenance dose of vitamin K antagonists (VKAs) according to
Study | Note | Type of VKAs | Maintenance dose (mg/week) | |||||
---|---|---|---|---|---|---|---|---|
TT type | CT type | CC type | ||||||
Mean | N | Mean | N | Mean | N | |||
Campos EIF |
- | Warfarin | 29.9 ± 18.9 | 24 | 28.3 ± 12.5 | 57 | 33.0 ± 15.8 | 55 |
de Oliveira Almeida VC |
- | Warfarin | 55.8 ± 38.3 | 54 | 45.5 ± 28.7 | 46 | 39.7 ± 26.6 | 16 |
Issac MS |
- | Warfarin | 49 [28-54.30] | 13 | 42 [35-49] | 46 | 35 [28-45.50] | 25 |
Kim Y |
European Americans | Warfarin | 55.57 ± 14.20 | 23 | 60.14 ± 17.76 | 35 | 58.58 ± 14.25 | 16 |
African Americans | 65.92 ± 22.18 | 6 | 58.45 ± 16.01 | 18 | 64.68 ± 21.03 | 35 | ||
Hispanic Americans | 50.75 ± 6.06 | 4 | 53.16 ± 15.44 | 26 | 51.63 ± 12.04 | 12 | ||
Asian Americans | 42.00 ± 0.0 | 3 | 52.85 ± 5.82 | 11 | 49.00 ± 5.35 | 7 | ||
Total | 55.63 ± 15.39 | 36 | 56.94 ± 15.91 | 90 | 59.48 ± 17.98 | 70 | ||
Li W |
- | Warfarin | 17.01 ± 5.6 | 29 | 18.69 ± 6.51 | 100 | 20.72 ± 8.89 | 85 |
Tavares LC |
Caucasian | Warfarin | 26.8 ± 0.7 (SE) | 44 | 27.3 ± 0.6 (SE) | 115 | 30.0 ± 0.7 (SE) | 74 |
non-Caucasian | 25.1 ± 2.0 (SE) |
14 | 29.88 ± 1.0 (SE) |
38 | 35.3 ± 1.3 (SE) |
24 | ||
Total | 26.2 ± 0.6 (SE) |
58 | 28.0 ± 0.5 (SE) |
153 | 30.5 ± 0.6 (SE) |
98 | ||
Gschwind L |
- | Acenocoumarol | 16.17 ± 8.46 | 22 | 14.77 ± 5.11 | 57 | 13.72 ± 4.90 | 36 |
Jiménez-Varo E |
Algorithm cohort | Acenocoumarol | 15 [11-19] | 31 | 13 [10-18] | 67 | 12 [8-18] | 36 |
Saraeva RB |
≤7 mg/week, n (%) 7-28 mg/week, n (%) ≥28 mg/week, n (%) |
Acenocoumarol | 1 (6.3) 9 (56.3) 6 (37.5) |
16 | 8 (15.7) 34 (66.7) 9 (17.6) |
51 | 5 (17.2) 20 (69.0) 4 (13.8) |
29 |
Sychev DA |
- | Acenocoumarol | 21.7 ± 6.02 | 15 | 18.48 ± 7.07 | 25 | 24.15 ± 9.38 | 10 |
†haplotype study; *